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 Disc diffusion was accurate for predicting the resistance status of clinical E. coli. 
 Disc diffusion was less accurate for predicting the susceptible status of isolates. 
 Breakpoints derived from statistical models improved disc diffusion performance. 




The assessment of antimicrobial resistance in bacteria derived from animals is often 
performed using the disc diffusion assay. However broth-microdilution is the preferred assay 
for national antimicrobial resistance surveillance programs. This study aimed to evaluate the 
accuracy of disc diffusion relative to broth-microdilution across a panel of 12 antimicrobials 
using data from a collection of 994 clinical Escherichia coli isolates from animals. Disc 
diffusion performance was evaluated by diagnostic sensitivity, specificity, likelihood ratio 
pairs and receive-operating characteristic (ROC) analysis. Data was dichotomised using CLSI 
susceptible and resistant clinical breakpoints. In addition, disc diffusion breakpoints produced 
using diffusion Breakpoint Estimation Testing Software (dBETS) were evaluated. Analysis 
revealed considerable variability in performance estimates for disc diffusion susceptible and 
resistant breakpoints (AUC ranges: 0.78 - 0.99 and 0.92 - 1.0, respectively) across the panel 
of antimicrobials. Ciprofloxacin, tetracycline, and ampicillin estimates were robust across 
both breakpoints, whereas estimates for several antimicrobials including amoxicillin-
clavulanic acid, cefoxitin and gentamicin were less favourable using susceptible breakpoints. 
Overall performance estimates were moderately improved when dBETS susceptible 













resistance of clinical E. coli from animals that could otherwise be determined by broth-
microdilution. While disc diffusion is suboptimal for assessing the proportion of fully 
susceptible isolates for some drugs, sensitivity and specificity estimates provided here allow 
for the use of standard formula to correct this. For this reason, disc diffusion has applicability 
in national surveillance provided the performance of the assay is taken into account. 
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Introduction 
The emergence and spread of bacteria resistant to multiple antimicrobials including 
‘last-line of defence’ drugs is a critical threat to the well-being of humans, animals and the 
environment. Strong international consensus for global action on antimicrobial resistance 
(AMR) has been established within the United Nations General Assembly (United Nations, 
2016) and international agencies responsible for human health, animal health and agriculture 
(OIE, 2015; WHO, 2015b). National surveillance programs are the cornerstone in global 
efforts to contain the spread of AMR (WHO, 2015a). Integrated national surveillance 
involving the coordinated collection of data on AMR in humans, animals and the 
environment is critical for detecting emerging forms of resistance and evaluating the success 
of policies designed to contain AMR (Laxminarayan et al., 2013). 
Surveillance of AMR in animal-derived bacteria is typically focussed on commensal 
and zoonotic bacteria from food-producing animals rather than clinical isolates from diseased 













greatest health threat to humans, commensal organisms of the gastrointestinal tract such as 
Escherichia coli are also considered high-risk for the transmission of antimicrobial resistance 
genes to human bacteria via food products (Shaban et al., 2014). A barrier to achieving 
comprehensive surveillance of all AMR risks in animals is the acquisition of data from a 
sufficient number of clinical isolates. This could be overcome by collecting antimicrobial 
assay results from veterinary laboratories either as minimum inhibitory concentration (MIC) 
from dilution-based assays or millimetres of zone diameter from diffusion-based assays. The 
MIC is widely considered to be the superior measure for quantifying an isolate’s 
susceptibility to antimicrobials (Turnidge and Paterson, 2007), and hence, broth-
microdilution is the preferred susceptibility assay for national surveillance programs (ISO, 
2006; OIE, 2017b). However, disc diffusion is often favoured by veterinary laboratories as it 
is affordable and readily customisable for a range of animal pathogens. There is considerable 
scope to merge susceptibility data acquired from disc diffusion from multiple laboratories 
into national surveillance provided the results are comparable to those from MIC assays. 
The overall accuracy of disc diffusion relative to broth-microdilution remains 
inconclusive despite several previous studies having evaluated the assay’s performance 
across a range of bacterial species and antimicrobials (Benedict et al., 2013; Hoelzer et al., 
2011; Klement et al., 2005; Rhodes et al., 2014; Saini et al., 2011; Schumacher et al., 2001). 
This may be due to limitations of isolates entering such studies including small sample size, 
study validity (i.e. isolates are not obtained from an epidemiologically relevant population 
from which inferences can be drawn) and low prevalence of resistance to antimicrobials, 
particularly those that are critically important to humans. For instance, of those studies which 
include animal-derived E. coli, only Benedict et al (2013) (n= 3362), Klement et al (2005) 
(n=231) and Rhodes (2014) (n= 304) assessed more than 200 isolates. Many previous studies 













observed agreement of dichotomous results, simple linear regression and error-rate bounding 
without considering modern statistical approaches that fully exploit the data to aid 
interpretation of test performance. 
Inevitably the assessment of diagnostic test accuracy relies on the reference test 
(usually broth-microdilution) and the cut-point (or breakpoint) used to dichotomise the data. 
In the context of AMR, the clinical breakpoint may define full susceptibility (susceptible 
breakpoint), resistance (resistant breakpoint) or the non-susceptible population (i.e. the 
combination of resistant and intermediate isolates) based on available pharmacokinetic data. 
In the evaluation of disc diffusion performance, some studies have applied the resistant 
breakpoint (Benedict et al., 2013; Hoelzer et al., 2011) while others applied the susceptible 
breakpoint (Klement et al., 2005; Saini et al., 2011). Inevitably different breakpoints will 
yield different estimates of test accuracy, with a resultant trade-off between the two types of 
misclassification errors – false negatives and false positives. While both misclassification 
errors have consequences, false negatives (i.e. classified susceptible when truly resistant) are 
the least desired in the clinical setting. Given the breakpoint is crucial for overall assessment 
of test performance, inconsistency in the use of breakpoints to dichotomise data across 
studies is likely to also be a key factor in the reported variable performance of disc diffusion 
relative to MIC-based assays. This is particularly relevant when the diagnostic test is used for 
different purposes as is the case in the clinical setting versus broad-scale surveillance. The 
receiver-operating characteristic (ROC) analysis addresses this by estimating the overall 
diagnostic accuracy of tests with continuous outcomes across all potential breakpoints. 
Therefore, the aim of this study was to develop a robust statistical approach to 
evaluate the accuracy of zone diameter measurements obtained by disc diffusion relative to 
MIC measurements obtained by broth-microdilution. The approach uses ROC analysis to 













(from the same isolates) across a large collection of clinical E. coli isolates from animals. 
Twelve antimicrobials relevant to animal health and public health were included for 
evaluation. For completeness, accuracy was evaluated using both susceptible and resistant 
clinical breakpoints recommended by the Clinical Laboratory Standards Institute (CLSI). In 
addition, new disc diffusion clinical breakpoints were produced using the model-based 






Data used in this study were derived from the first nation-wide survey for 
antimicrobial resistance in veterinary pathogens, which took place between January 2013 and 
January 2014 with the cooperation of all veterinary diagnostic laboratories (n = 22) in 
Australia (Abraham et al., 2015). The data included disc diffusion and broth-microdilution 
results from 994 clinical E. coli isolates from canine (n = 510), feline (n = 338), equine (n = 
28), and other species (n = 118), excluding food-producing animals. 
Antimicrobial susceptibility testing 
E. coli isolates underwent disc diffusion and broth-microdilution testing according to 
CLSI VET01-A4 protocols (CLSI, 2013). The MIC results for the isolate collection were 
obtained from a previous study (Saputra et al, under review Vet Microbiol). Disc diffusion 
testing was performed independently and at a different point in time to when broth-













The dataset was dichotomised for each antimicrobial and both assays using the susceptible 
and resistant clinical breakpoints specified in CLSI performance standards VET01-S3 (CLSI, 
2015a) and M100-S25 (CLSI, 2015b) (Table 1). For dichotomisation using the susceptible 
clinical breakpoint, isolates clinically referred to as ‘intermediate’ or ‘resistant’ were 
collectively classified as ‘non-susceptible’. For dichotomisation using the resistant clinical 
breakpoint, isolates were classified as ‘susceptible’ if their measurement value fell in the 
susceptible or intermediate range. Where animal-specific clinical breakpoints were 
unavailable or did not have corresponding MIC and zone diameter breakpoints, human 
clinical breakpoints were used as indicated. The exception was cefovecin as there were no 
CLSI clinical breakpoints available, so MIC and zone diameter susceptible and resistant 
breakpoints were used according to the manufacturer’s recommendations. In this paper, 
unless otherwise specified, reference to susceptible and resistant MIC and zone diameter 
breakpoints refer to the CLSI recommended clinical breakpoints. 
Statistical Analysis 
Relative diagnostic accuracy 
The accuracy of disc diffusion classification relative to MIC (the reference method) 
was evaluated by estimating relative diagnostic sensitivity, diagnostic specificity, likelihood 
ratios of positive and negative results, and summarised using receiver-operating characteristic 
(ROC) analysis. MIC and zone diameters were compared using non-parametric ROC analysis 
since MIC data cannot be assumed to be normally distributed. For a given breakpoint, 
likelihood ratio pairs summarise how many times more (or less) likely a resistant isolate will 
be classified as resistant then an isolate that is fully susceptible. The likelihood ratio describes 













ratios and area-under the ROC-curve (AUC) estimations are given elsewhere (Greiner and 
Gardner, 2000). 
Agreement estimation 
Observed agreement was calculated as the proportion of isolates with the same AMR 
clinical classification by disc diffusion and broth-microdilution (i.e. both test results were 
within the susceptible breakpoint range, or within the resistant breakpoint range). McNemar’s 
mid-p test (Fagerland et al., 2013) was used to assess significance (two-tailed p < 0.05) in the 
extent of disagreement between the two tests. The mid-p version of the McNemar’s test was 
used instead of the conventional McNemar’s test as the count of discordant results between 
the two methods was often less than 25. Prevalence adjusted, bias adjusted kappa (PABAK) 
was calculated as a measure of agreement to adjust for imbalances caused by extreme 
prevalence and bias between tests (Byrt et al., 1993). 
dBETS disc diffusion breakpoint values 
The recently published diffusion Breakpoint Estimation Testing Software (dBETS) 
program (https://dbets.shinyapps.io/dBETS/, accessed 25 April 2017) was used to generate 
zone diameter susceptible and resistant clinical breakpoints for the antimicrobials evaluated 
in this dataset (DePalma et al., 2017). The dBETS program was used to apply spline-based 
probability models to account for disc diffusion assay variability, providing an advantage 
over commonly used methods such as the modified error-rate bounded method. 
Data was imported from MS excel files into Stata version 14.1 (Stata Corporation, 
College Station, TX) for analysis. For each isolate and each of the 12 antimicrobials tested, 















For eleven antimicrobial agents, 994 paired observations on zone diameter by disc 
diffusion and MIC by broth-microdilution were available for analysis. For cefovecin, 948 
paired observations were available. The overall performance of disc diffusion relative to 
broth-microdilution was very strong for ten antimicrobials (two antimicrobials were not 
evaluated due to insufficient data) at the resistant breakpoints (AUC range: 0.92-1.0) (Table 
2). However at susceptible breakpoints, overall performance for all 12 antimicrobials was 
appreciably lower (AUC range: 0.78-0.99) (Table 2). At the susceptible breakpoint, 
sensitivity and specificity (reflected by AUC) varied across the antimicrobial panel, and was 
suboptimal for amoxicillin-clavulanic acid (AUC, 0.82), cephalothin (AUC, 0.82), cefoxitin 
(AUC, 0.78) and gentamicin (AUC, 0.82). Performance estimates for ciprofloxacin, 
trimethoprim-sulfamethoxazole and tetracycline were relatively unaffected by the choice of 
breakpoint (Table 2). AUC estimates could not be determined for amikacin and imipenem as 
the isolates were all susceptible by the reference method. 
Visual comparison of ROC plots for ciprofloxacin, ceftiofur, cefovecin, ceftiofur, 
cephalothin, tetracycline and cefoxitin are presented in Fig 1. Here, two ROC curves are 
plotted on each graph to demonstrate the accuracy of disc diffusion relative to broth-
microdilution using the MIC susceptible and resistant breakpoints. For ciprofloxacin, 
ceftiofur, and tetracycline both susceptible and resistant ROC plots show near perfect test 
discrimination (both curves approach the top left corner of the graph). In contrast, cefovecin, 
cephalothin, and cefoxitin have higher levels of misclassification error (curves distant from 
the top left hand corner of the graph) (Fig 1). 
Table 2 shows that when resistant breakpoints were applied, relative specificity was 













(range, 0.72 – 0.99). When susceptible breakpoints were applied, relative specificity (range, 
0.81 - 1.0) and sensitivity (range, 0.23 – 0.96) estimates were notably more variable. By these 
criteria, disc diffusion performed poorly for several antimicrobials especially amoxicillin-
clavulanic acid, cefoxitin and gentamicin. When interpreting a positive disc diffusion result, 
using resistant breakpoints provided stronger evidence (large LR+) compared to susceptible 
breakpoints (LR+ ranges: 21-454.6 and 3.7-220.6, respectively) (Table 3). Similarly, the 
evidence provided by negative disc diffusion results were stronger (small LR-) when using 
resistant breakpoints compared to susceptible breakpoints (LR- ranges: 0.01-0.28 and 0.04-
0.79, respectively). Evidence from a positive disc diffusion result was weakest for 
cephalothin and ampicillin (lowest LR+) and strongest for ciprofloxacin (highest LR+) 
regardless of the breakpoint (Table 3). Evidence from a negative disc diffusion result was 
weakest for amoxicillin-clavulanic acid (highest LR-) and strongest for ciprofloxacin (lowest 
LR-) (Table 3). 
Two-graph receiver-operating characteristic (TG-ROC) plots for disc diffusion 
relative to broth-microdilution shows the impact of breakpoint on sensitivity and specificity 
and hence the level of misclassification error (Fig 2). Sensitivity and specificity are equal at 
the point where the two lines intersect on the TG ROC plot, however the point of intersection 
does not always equate to the optimal breakpoint since the cost of misclassification errors 
almost always differs. CLSI and dBETS zone diameter breakpoints are plotted for 
comparison. For ciprofloxacin, CLSI and dBETS susceptible and resistant breakpoints 
correspond to almost perfect specificity with optimal sensitivity estimates (Tables 2 and 5). 
Similarly using both approaches, breakpoints for cefovecin and trimethoprim-
sulfamethoxazole target the highest specificity and albeit with correspondingly lower 













Observed agreement estimates were strong for most antimicrobials on resistant 
breakpoints (range, 0.94 - 1.0), but highly variable using susceptible breakpoints (range, 0.39 
- 0.99) (Table 4). (Supplementary Tables 3 and 4 outline the contribution of positive 
agreement and negative agreement towards overall observed agreement estimates using 
susceptible and resistant breakpoints). Antimicrobials with greater than 1% difference 
between proportion resistant by broth-microdilution and proportion resistant by disc diffusion 
recorded a statistically significant (p <0.05) mid-p value McNemar’s test (Table 4). 
Amoxicillin-clavulanic acid, cephalothin and cefoxitin recorded excessively large differences 
between the proportions resistant by broth-microdilution and disc diffusion based on 
susceptible breakpoints. These three antimicrobials also performed sub-optimally when inter-
test agreement was measured by PABAK (Table 4). Antimicrobials with the lowest disc 
diffusion performance estimates also had increased overlapping susceptible and non-
susceptible populations (Fig. 3). Disc diffusion estimates of accuracy are optimised when 
there is clear separation of ‘susceptible’ and ‘non-susceptible’ populations as demonstrated 
on the zone diameter histograms for ciprofloxacin, tetracycline, and ceftiofur (Fig. 3). 
However, disc diffusion estimates are weaker when susceptible and non-susceptible 
populations overlap (e.g. amoxicillin-clavulanic acid, cephalothin, and cefoxitin). 
Improved disc diffusion performance estimates were produced when dBETS zone 
diameter susceptible breakpoints were applied (Table 5). This was particularly evident for 
amoxicillin-clavulanic acid where sensitivity went from 0.23 using the CLSI susceptible 
breakpoint to 0.61. However cefoxitin (CLSI: 0.33; dBETS 0.43) and gentamicin (CLSI: 
0.50, dBETS: 0.50) estimates were minimally improved. At the resistant breakpoint, disc 
diffusion performance was relatively unchanged when the dBETS values were applied. At 
dBETS susceptible breakpoint, observed agreement for many of the antimicrobials evaluated 















Inferences made in this work are based on a large number of clinical E. coli isolates 
(n=994) from multiple animal species, and procured from a formal survey involving all major 
veterinary laboratories in Australia. The most notable finding of this study is the marked 
superiority in the performance of disc diffusion relative to broth-microdilution when assessed 
on resistant breakpoints compared to susceptible breakpoints. When resistant breakpoints are 
applied to broth-microdilution results, a very high level of disc diffusion relative accuracy is 
evident for the majority of antimicrobials evaluated, particularly for critically important 
antimicrobials (i.e. fluoroquinolones and third-generation cephalosporins). In comparison, 
disc diffusion performance was lower for most antimicrobials at susceptible breakpoints. This 
study also provides dBETS zone diameter breakpoints which have a greater objective basis 
than the current approach used to establish CLSI zone diameter breakpoints. The 
performance of disc diffusion for amoxicillin-clavulanic acid, cefoxitin and gentamicin was 
particularly sensitive to the choice of breakpoints, resulting in highly variable sensitivity 
estimates and large discrepancies in observed agreement. Cephalothin and trimethoprim-
sulfamethoxazole had poor disc diffusion performance estimates regardless of the breakpoint 
used to dichotomise the data. 
Observations arising from this study demonstrate that disc diffusion is appropriate to 
differentiate a population of clinical E. coli isolates derived from animals using CLSI or 
dBETS zone diameter resistant breakpoints for the majority of antimicrobials assessed in this 
study. However, for several antimicrobials including amoxicillin-clavulanic acid, cefoxitin 
and gentamicin, disc diffusion has limitations when differentiating a population of clinical E. 













breakpoints generated by dBETS are sometimes superior and should be considered when 
breakpoints are established. These findings also inform on the selection of antimicrobials for 
inclusion in national surveillance, with disc diffusion estimates for ciprofloxacin ceftiofur, 
ampicillin and tetracycline proving robust across breakpoints. 
The study outcomes also support improved clinical decision-making by providing 
robust estimates of sensitivity and specificity for disc diffusion that hitherto have been rarely 
reported. These parameters, along with likelihood ratio pairs and ROC analysis, are key 
metrics relied upon in evidence-based approaches to clinical decision-making and the 
assessment of diagnostic test performance (Dohoo et al., 2009; OIE, 2017a). Moreover in a 
surveillance setting, the ‘true’ prevalence (Rogan and Gladen, 1978) of resistance in a 
population can be estimated if sensitivity and specificity are known. Calculating true 
prevalence from sensitivity and specificity will adjust for the inaccuracy of disc diffusion (i.e. 
apparent prevalence) and allow for comparison of zone diameter prevalence with MIC 
prevalence. This will improve the validity of surveillance data obtained from clinical E. coli 
isolates from animals. Thus, the quantitative estimates of test performance provided here for 
a broad panel of antimicrobials stands to benefit both population health and clinical medicine. 
ROC analysis is useful to determine test accuracy and assist in defining breakpoint 
values however, only a small number of microbiology studies have utilised ROC analysis for 
determination of performance of phenotypic susceptibility assays in veterinary isolates (Jean 
et al., 2015; Klement et al., 2005; Saini et al., 2011; Schumacher et al., 2001). Hanzcar et al 
(2010) identified the need for large sample sizes in ROC estimation of assay performance 
(Hanczar et al., 2010) which has been achieved in this study. Although efforts have been 
made to utilise ROC analysis for veterinary pathogens, the sample size in such studies has 













sample of 25 E. coli isolates, and Klement et al (2005) used 231 E. coli isolates from bovine 
milk samples. 
Discrepancies in disc diffusion performance estimates for some antimicrobials found 
here are in agreement with other studies (Hombach et al., 2013; Klement et al., 2005). While 
variable performance estimates may be attributed to biological differences, technical 
limitations (including laboratory error), or true variation in the disc diffusion test, the 
appropriateness of the breakpoints must also be considered. Not all antimicrobials evaluated 
in this study have breakpoints specific for veterinary isolates, making it necessary to use 
human breakpoints. This has likely resulted in variable disc diffusion performance estimates 
for some drugs. Additionally for trimethoprim-sulfamethoxazole, the trailing endpoint 
phenomenon seen with MIC assays (Jorgenson and Turnidge, 2015) may be responsible for 
variability in disc diffusion performance results. Epidemiological cut off points (ECOFFs) are 
often used as the basis for performing surveillance (Silley, 2012). However, owing to the 
existing complexity of this study (involving 12 antimicrobials and use of two breakpoints) 
ECOFFs were not included in the analysis. Nevertheless, ECOFFs for a given drug are often 
similar to, or lower than CLSI susceptible breakpoints and the conclusion of reduced test 
accuracy for disc diffusion compared to broth microdilution will also hold for interpretations 
based on ECOFFs. It was also evident in this study that overlapping susceptible and non-
susceptible populations resulted in misclassification errors. In this study, misclassification 
errors were retained to replicate the imperfections that would likely occur if the veterinary 
laboratory network were to submit routine disc diffusion data for use in national surveillance. 
The dBETS method appeared relatively robust to outliers for most of the antimicrobials 
assessed. 
Limitations associated with this study should be considered. This study only 













pathogenic (commensal) E. coli from healthy animals typically included in AMR 
surveillance. Data for this study was generated in a single laboratory and does not 
accommodate the possibility of laboratory-to-laboratory variation (reproducibility) in test 
performance. Broth-microdilution is an imperfect reference test and the performance 
estimates for disc diffusion can never exceed those of broth-microdilution. Theoretically, 
better disc diffusion accuracy estimates can be obtained by latent class analysis (Pepe and 
Janes, 2007) which is not reliant on a perfect reference test, however the assumptions that 
underlie this approach precludes its use in this study. While accuracy measures such as 
sensitivity, specificity, and AUC provide the best available evidence of inter-test 
compatibility, agreement measures such as observed agreement, McNemars test, and inter-
test agreement have been reported in this study to facilitate comparison with previous studies. 
In the future, the existing isolate collection will be expanded to aid in the development of 
clinical breakpoints unique for animal species, disease syndromes or combinations of these. 
 
Conclusion 
We have demonstrated that for most antimicrobials, disc diffusion was shown to be 
accurate at predicting the resistance status of animal-derived clinical E. coli that could 
otherwise be obtained by broth-microdilution. However, for a sub-set of antimicrobials disc 
diffusion demonstrated inferior performance relative to broth-microdilution and this warrants 
further investigation. Although disc diffusion performance at the susceptible breakpoint is 
suboptimal, standard equations can be applied to correct this. Moreover, these findings 
inform on the selection of antimicrobials for inclusion in national surveillance, with disc 
diffusion performing well for critically important antimicrobial classes such as 













appears to have applicability in national surveillance provided performance of the assay, as 
defined in this work, is taken into account. 
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Table 1 Disc diffusion and broth-microdilution interpretative criteria for twelve antimicrobials evaluated in this study and applied to 994 clinical 
Escherichia coli isolates derived from animals. 
  Susceptible Breakpoints Resistant Breakpoints  
















AMC ≥18* ≤8* ≤13* ≥32* 1.0 – 64 
Amikacin AMK ≥17* ≤16* ≤14* ≥64* 0.5 – 64 
Ampicillin AMP ≥17* ≤8* ≤13* ≥32* 1.0 – 128 
Cephalothin CEF ≥18* ≤8* ≤14* ≥32* 2.0 – 128 
Ceftiofur CFT ≥21* ≤2* ≤17* ≥8* 0.06 – 64 
Ciprofloxacin CIP ≥21† ≤1† ≤15† ≥4† 0.008 – 8 
Cefovecin CVN ≥23^ ≤2^ ≤19^ ≥8^ 0.12 – 128 
Cefoxitin FOX ≥18† ≤8† ≤14† ≥32† 1.0 – 128 
Gentamicin GEN ≥16* ≤2* ≤12* ≥8* 0.12 – 64 
Imipenem IPM ≥23* ≤1* ≤19* ≥4* 0.06 – 4 
Trimethoprim-
sulfamethoxazole 
SXT ≥16* ≤2* ≤10* ≥4* 0.12 – 16 
Tetracycline TET ≥19* ≤4* ≤14* ≥16* 0.12 – 128 
* Derived from CLSI VET01-S3. 
† Derived from CLSI M100-S25. 













Table 2 Diagnostic performance estimates of disc diffusion relative to broth-microdilution for 994 clinical Escherichia coli isolates from 
animals using CLSI susceptible and resistant breakpoints. DSe, diagnostic sensitivity; DSp diagnostic specificity; AUC, area under the curve. 
Exact 95% confidence intervals are given in supplementary materials.  
 Susceptible Breakpoint Estimates Resistant Breakpoint Estimates 
Antimicrobial Relative DSe Relative DSp AUCa Relative DSe Relative DSp AUC
Amoxicillin-
clavulanic acid 
0.23 0.99 0.82 0.79 0.99 0.98 
Amikacin NA 0.99 NA NA 1.0 NA 
Ampicillin 0.93 0.81 0.96 0.97 0.95 0.98 
Cephalothin 0.70 0.81 0.82 0.75 0.98 0.92 
Ceftiofur 0.84 0.99 0.94 0.94 0.99 0.98 
Ciprofloxacin 0.96 1.0 0.99 0.99 1.0 1.0 
Cefovecin 0.67 0.96 0.87 0.88 0.99 0.97 
Cefoxitin 0.33 1.0 0.78 0.83 0.99 0.97 
Gentamicin 0.50 0.99 0.82 0.92 1.0 0.97 
Imipenem NA 0.99 NA NA 1.0 NA 
Trimethoprim-
sulfamethoxazole 
0.70 0.99 0.93 0.72 0.99 0.94 
Tetracycline 0.93 0.98 0.97 0.95 0.99 0.98 
NA, not available due to insufficient data for the analysis. 
Table 3 Estimates of likelihood ratios of disc diffusion relative to broth-microdilution for 994 clinical Escherichia coli isolates using CLSI 
susceptible and resistant breakpoints. LR+, likelihood ratio of a positive test result; LR-, likelihood ratio of a negative result. Exact 95% 
confidence intervals are given in the supplementary materials. 













Antimicrobial LR+ LR- LR+ LR- 
Amoxicillin-
clavulanic acid 
15.8 0.79 118.1 0.21 
Amikacin NA NA NA NA 
Ampicillin 4.8 0.09 21.0 0.03 
Cephalothin 3.7 0.37 35.4 0.25 
Ceftiofur 67.3 0.16 168.4 0.06 
Ciprofloxacin 220.6 0.04 454.6 0.01 
Cefovecin 17.2 0.34 131.2 0.12 
Cefoxitin 61.8 0.67 124.9 0.18 
Gentamicin 63.3 0.51 289.3 0.08 
Imipenem NA NA NA NA 
Trimethoprim-
sulfamethoxazole 
68.8 0.31 72.9 0.28 
Tetracycline 53.5 0.07 154.4 0.05 
NA, not available due to insufficient data for the analysis. 
Table 4 Agreement estimates between broth-microdilution and disc diffusion for 994 clinical Escherichia coli isolates from animals using CLSI 
susceptible and resistant breakpoints. Exact 95% confidence intervals for estimates are in supplementary materials. BMD, broth-microdilution; 
DD, disc diffusion. 






















0.79 0.18 <0.001* 0.39 NA 0.10 0.09 <0.001* 0.97 0.95 
Amikacin 0.02 0.01 0.02* 0.97 0.94 0.02 0.02 0.63 1.0 NA 













Cephalothin 0.92 0.66 <0.001* 0.71 0.41 0.20 0.17 <0.001* 0.94 0.87 
Ceftiofur 0.11 0.11 0.20 0.97 0.94 0.10 0.10 0.77 0.99 0.98 
Ciprofloxacin 0.08 0.08 0.73  0.99 0.99 0.07 0.07 0.63 1.0 0.99 
Cefovecin 0.15 0.14 0.08 0.92 0.84 0.10 0.10 0.17 0.98 0.97 
Cefoxitin 0.25 0.09 <0.001* 0.83 0.65 0.09 0.08 0.05* 0.98 0.96 
Gentamicin 0.10 0.06 <0.001* 0.94 0.89 0.05 0.05 0.73 0.99 0.99 
Imipenem 0.04 0.02 <0.001* 0.95 0.89 0 0 0.2 1.0 0.99 
Trimethoprim-
sulfamethoxazole 
0.21 0.15 <0.001* 0.93 0.86 0.19 0.15 <0.001* 0.94 0.88 
Tetracycline 0.19 0.19 0.85 0.97 0.95 0.18 0.18 0.30 0.99 0.97 
NA, not available due to insufficient data for analysis. 
* Significant mid-p McNemar’s chi-square test (p<0.05). 
Table 5 Estimates of accuracy of disc diffusion relative to broth-microdilution for 994 clinical Escherichia coli isolates from animals using zone 
diameter interpretative criteria produced from the dBETS program. DSe, diagnostic sensitivity; DSp diagnostic specificity; ZD, zone diameter. 
Exact 95% confidence intervals for estimates provided in supplementary materials. 
 dBETS Susceptible Breakpoint Estimates dBETS Resistant Breakpoint Estimates 




















21 0.70 0.87 0.66 15 0.92 0.98 0.98 
Amikacin 16 NA 1.0 0.97 12 NA 1.0 1.0 
Ampicillin 11 0.80 0.98 0.92 7 0.96 0.98 0.97 
Cephalothin 18 0.70 0.81 0.71 13 0.68 0.99 0.93 
Ceftiofur 22 0.86 0.98 0.97 18 0.96 0.99 0.99 













Cefovecin 23 0.67 0.96 0.92 19 0.88 0.99 0.98 
Cefoxitin 22 0.43 0.97 0.83 18 0.91 0.99 0.98 
Gentamicin 16 0.50 0.99 0.94 12 0.92 1.0 0.99 
Imipenem 23 NA 0.99 0.95 15 NA 1.0 1.0 
Trimethoprim-
sulfamethoxazole 
25 0.87 0.86 0.86 21 0.79 0.98 0.94 
Tetracycline 18 0.93 0.99 0.97 13 0.95 0.99 0.98 














Fig 1. ROC plots demonstrating overall performance of disc diffusion relative to broth-
microdilution assays in clinical Escherichia coli isolates from animals for six 
antimicrobials. The black-closed-dot curve and the open-diamond-dash curve represent the 
dichotomisation at resistant and susceptible breakpoints respectively. CIP, ciprofloxacin; 














Fig 2. Two-graph ROC (TG-ROC) plots of disc diffusion performance relative to broth-













sulfamethoxazole (SXT). The TG-ROC curves for (a) susceptible and (b) resistant 
breakpoints are represented in the left and right column (a) and (b) respectively. Relative 
sensitivity (blue solid line), relative specificity (red dash line), CLSI breakpoint (black solid 














Fig 3. Distribution of zone diameter results for clinical E. coli isolates derived from 













susceptible breakpoint (blue long-dash line) is plotted over each distribution. AMC, 
amoxicillin-clavulanic acid; CIP, ciprofloxacin; CEF, cephalothin; TET, tetracycline; FOX, 
cefoxitin; CFT, ceftiofur. 
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